

Submitter: Kathleen Wilson  
On Behalf Of:  
Committee: House Committee On Behavioral Health  
Measure, Appointment or Topic: HB4110

Attention House Committee On Behavioral Health. I do support this HB 4110. I do have concerns about the doctor prescribing this medication. I think it needs more trial studies. I would refer that you read this article regarding IBOGAIN.

Foundations' newsletter regarding Psychedelic.Gregory Ferenstein December 17, 2025

Attention House Committee on Behavioral Health, I support HB 4110. I would suggest that this Bill be clarified

Welcome to Reason Foundation's newsletter on psychedelics policy. This edition covers: (this article was dated Dec 2025)

A real-world study on mental health outcomes from Oregon's legal market. A series of educational documents on ibogaine legalization was provided to state lawmakers Department of Health and Human Services leadership attends Make America Healthy Again Summit, State round-up, Oregon study: Real-world benefits Preliminary evidence from a groundbreaking new study is the first to confirm positive public health benefits from Oregon's regulated market of psilocybin services. Participants showed significant reductions in anxiety and depression, alongside improvements in general well-being, in pre- and post-experience surveys using established questionnaires. The study could have important policy implications as the federal Department of Health and Human Services (HHS) evaluates whether psilocybin should remain a Schedule I drug.

Oregon

Voter Kathleen Wilson